Vir Biotechnology宣布,其靶向前列腺特异性膜抗原(PSMA)的Pro-Xten®双掩蔽T细胞衔接器VIR-5500已获得美国食品药品监督管理局(FDA)授予的快速通道资格,用于前列腺癌的治疗。
Vir Biotechnology宣布,其靶向前列腺特异性膜抗原(PSMA)的Pro-Xten®双掩蔽T细胞衔接器VIR-5500已获得美国食品药品监督管理局(FDA)授予的快速通道资格,用于前列腺癌的治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.